See a complete PubMed list of publications by Christine Walsh, MD, MS.

Selected Key Publications

Hodeib M, Cohen JG, Mehta S, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I. Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN. Gynecol Oncol. 2016 Jun;141(3):507-510.

Beach JA, Aspuria PJ, Cheon DJ, Lawrenson K, Agadjanian H, Walsh CS, Karlan BY, Orsulic S. Sphingosine kinase 1 is required for TGF-β mediated fibroblastto- myofibroblast differentiation in ovarian cancer. Oncotarget. 2016 Jan 26;7(4):4167-4182.

Walsh CS, Hodeib M. Leveraging DNA repair deficiency in gynecologic oncology. Curr Opin Obstet Gynecol. 2016 Feb;28(1):24-31.

Walsh CS. The more you look, the more you will find. Cancer. 2015 Oct 6. [Epub ahead of print.]

Zakhour M, LaBrant L, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I. Too much, too late: Aggressive measures and the timing of end of life care discussions in women with gynecologic malignancies. Gynecol Oncol. 2015 Aug;138(2):383-387.

Walsh CS. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015 May;137(2):343-350.

Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, Allen JR, Spurka L, Funari V, Spiteri E, Wang Q, Orsulic S, Walsh C, et al. Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget. 2015;6(2):696-714.

Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF. Breast cancer following ovarian cancer in BRCA mutation carriers. JAMA Surg. 2014 Dec;149(12):1306-1313.

Moschiano EJ, Barbuto DA, Walsh C, Singh K, Euscher ED, Roma AA, Ali-Fehmi R, Frauenhoffer EE, Montiel DP, Kim I, et al. Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites. Int J Gynecol Pathol. 2014 May;33(3):268-273.

Cohen JG, Tran AQ, Rimel BJ, Cass I, Walsh CS, Karlan BY, Li AJ. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival. Gynecol Oncol. 2014 Mar;132(3):556-559.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol. 2014 Feb;132(2):334-342.

Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ. Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013 Dec;131(3):609-612.

Diaz ES, Walts AE, Karlan BY, Walsh CS. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol. 2013 Dec;131(3):541-545.

Stoffel EM, Walsh C. Chemoprevention of endometrial cancer in Lynch syndrome: a step forward. Cancer Prev Res (Phila). 2013 Aug;6(8):755-759.

Alvarez Secord A, Walsh CS. Summary of the 44th Annual Meeting on Women's Cancers. Gynecol Oncol. 2013 May;129(2):273-276.

Penner KR, Dorigo O, Aoyama C, Ostrzega N, Balzer BL, Rao J, Walsh CS, Cass I, Holschneider CH. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol. 2012 Mar;124(3):542-548.